Skip to main content
Premium Trial:

Request an Annual Quote

Suzhou Ribo Life Sciences Takes License to Life Tech siRNA Drug-delivery Technology

Premium

Life Technologies announced this week that it has signed a licensing agreement giving Suzhou Ribo Life Sciences the exclusive rights to use its Invivofectamine Rx delivery technology in the development and manufacturing of siRNA therapeutics in China.

Life Technologies said that it stands to receive milestones and royalties on the sale of products incorporating the technology. Additional terms of the arrangement were not disclosed.

"Adding Life's Invivofectamine Rx formulation technology into our development efforts will significantly increase our ability to bring new siRNA therapeutics to Chinese patients with unmet medical needs," Ribo CEO Zicai Liang said in a statement. "We look forward to bringing our first Invivofectamine Rx-based program targeting hepatitis B into the clinic in a relatively short period of time."

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.